DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

324
SECTION II
NEUROPHARMACOLOGY
Table 12–5
Summary of Adrenergic Agonists and Antagonists (continued)
PROMINENT
PRINCIPAL
CLASS DRUGS PHARMACOLOGICAL ACTIONS THERAPEUTIC APPLICATIONS UNTOWARD EFFECTS COMMENTS
α-selective Prazosin b PVR and Primary hypertension Postural hypotension when PBZ produces
Terazosin blood pressure Increase urine flow in BPH therapy instituted long-lasting
Doxazosin Relax smooth muscles in α receptor blockade,
Trimazosin neck of urinary bladder can block neuronal
Alfuzosin and in prostate and extraneuronal
Tamsulosin
Silodosin
uptake of amines
Prazosin and related
quinazolines are
selective for α 1
receptors
Tamsulosin exhibits
some selectivity for
α 1A
receptors
β Blockers
Non-selective Nadolol b heart rate Angina pectoris Bradycardia Effects depend
(first generation) Penbutolol b contractility Hypertension Negative inotropy on sympatho-
Pindolol b cardiac output Cardiac arrhythmias b in cardiac output adrenal tone
Propranolol Slow conduction in atria CHF Bradyarrhythmias Bronchoconstriction
Timolol and AV node Pheochromocytoma b AV conduction (of concern in
a refractory period, Glaucoma Bronchoconstriction asthmatics and
AV node Hypertropic obstructive Fatigue COPD)
Bronchoconstriction cardiomyopathy Sleep disturbances Hypoglycemia
Prolonged hypoglycemia Hyperthyroidism (insomnia, nightmares) (of concern in
b plasma FFA Migraine prophylaxis Prolongation of hypoglycemics and
b HDL cholesterol Acute panic symptoms hypoglycemia diabetics)
a LDL cholesterol and Substance abuse withdrawal Sexual dysfunction in men Membrane stabilizing
triglycerides Variceal bleeding in Drug interactions effect (propranolol,
Hypokalemia portal hypertension and betaxolol)
ISA (strong for
pindolol; weak for
penbutolol, carteolol,
labetalol, and
betaxolol)